[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)

3.19.2014 |  British Medical Journal

A 21st Century Nosocomial Issue with Endoscopes

On 3 January 2014 the results of a year long investigation by the US Centers for Disease Control (CDC) into an outbreak of New Delhi metallo-β-lactamase (NDM)-producing carbapenem resistant Enterobacteriaceae (CRE) were released.  Of 69 patients with confirmed CRE infections, 29 went to Advocate Lutheran General Hospital (ALGH) for the same procedure—an endoscopy.  The endoscopy itself is not dangerous, but the current cleaning process used between procedures leaves patients susceptible to infection and troubles many healthcare practitioners.

For the full article, click here.